EX-99.1 2 tm2612166d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026 Phase 1 combination data of 6.5mg/m2 Q2W nuzefatide pevedotin plus nivolumab demonstrate an encouraging preliminary efficacy profile with a differentiated tolerability profile in previously treated metastatic urothelial cancer Nuzefatide pevedotin demonstrates potent preclinical anti-tumor activity across a broad range of pancreatic ductal adenocarcinoma (PDAC) and head and neck squamous cell carcinoma xenograft models Dose range finding studies identify 8mg/m2 Q2W as the preferred dose for monotherapy and first patient dosed in 2L+ PDAC Phase 2 trial Human imaging data provides further evidence of the potential of EphA2 as a novel cancer target and the positive properties of Bicycle® radioligand molecules for radiopharmaceutical use CAMBRIDGE, England & BOSTON, April 20, 2026 - Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced updates from its EphA2…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
BICYCLE THERAPEUTICS PLC
Other Events
Item 8.01. Other Events On April 20, 2026, Bicycle Therapeutics plc (the “Company”) issued a press release providing updates on its nuzefatide pevedotin program and the Company’s EphA2 pipeline. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.
Company context
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528, a Bicycle® Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009), a BDC® targeting Nectin-4, a well-validated tumor antigen; and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases in additional therapeutic areas.
Current securities
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 20, 2026
- Results of Operations and Financial ConditionJul 30, 2026
- 10-Q filingJul 30, 2026
- Submission of Matters to a Vote of Security HoldersJun 18, 2026
- Other EventsMay 21, 2026